The Role of Erythropoietin in Myelodysplastic Syndrome
NCT00723112 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8
Last updated 2010-11-23
Summary
The purpose of the study is to elucidate the causative molecular events responsible for the abnormal erythropoiesis in MDS.
Conditions
Sponsors & Collaborators
-
National Institutes of Health (NIH)
collaborator NIH - lead OTHER
Principal Investigators
-
Josef T Prchal, MD · University of Utah
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2007-02-28
- Primary Completion
- 2010-10-31
- Completion
- 2010-10-31
Countries
- United States
Study Locations
More Related Trials
-
Observatory of the Prescription of Erythropoietin as Treatment of Anemia Induced by Chemotherapy or Allograft Conditioning Among the Patients With a Haematological Malignancy
NCT02860598 ·Status: UNKNOWN
-
A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)
NCT02145026 ·Status: COMPLETED ·Phase: PHASE4
-
" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance "
NCT06983756 ·Status: NOT_YET_RECRUITING
-
Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Acid
NCT00437450 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
NCT00144495 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS
NCT03223961 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
An Open-label Trial to Determine Increased Red Blood Cell Production in Subjects With Anemia of Chronic Disease
NCT01846689 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
NCT00144482 ·Status: COMPLETED ·Phase: PHASE3
-
Danazol for Genetic Bone Marrow and Lung Disorders
NCT01441037 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Prevalence of Erythropoiesis Stimulating Agents Hyporesponsiveness in Dialysis Patients in Assiut University Hospital
NCT06053866 ·Status: NOT_YET_RECRUITING
-
A Study to Evaluate the Effectiveness and Safety of Epoetin Alfa During the Period When One is Donating One's Own Blood Before Surgery.
NCT00270179 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.
NCT01868477 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
NCT00446602 ·Status: WITHDRAWN ·Phase: PHASE2
-
Erythropoietin Resistance in Anemia of Chronic Kidney Disease
NCT00526747 ·Status: COMPLETED
-
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
NCT00058331 ·Status: COMPLETED ·Phase: PHASE3
-
CD71 in Dried Blood Spots in Healthy Males
NCT04073849 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Study of Patients With Pure Red Cell Aplasia Associated With Recombinant Human Erythropoietin Treatment
NCT00211042 ·Status: COMPLETED
-
Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction
NCT00367991 ·Status: COMPLETED ·Phase: PHASE2
-
Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation
NCT03010579 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study of Patients Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin Antibodies
NCT00210977 ·Status: WITHDRAWN
-
Search for Predictive Markers of Efficacy of ESAs in Patients With Non-myeloid Malignancies or Myelodysplastic Syndrome
NCT01546337 ·Status: TERMINATED
-
An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion
NCT03900715 ·Status: COMPLETED ·Phase: PHASE2
-
A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy
NCT00002072 ·Status: COMPLETED ·Phase: NA
-
Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma
NCT00400686 ·Status: COMPLETED ·Phase: NA
-
rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics
NCT02356419 ·Status: UNKNOWN ·Phase: PHASE1